REACHnet Celebrates Heart Month – Innovations in healthcare for people living with heart disease
February is Heart Month! Learn about research to improve healthcare for people living with heart disease.
LPHI’s Research Action for Health Network (REACHnet) – in partnership with Ochsner Health System, Tulane Heart & Vascular Institute, and Baylor Scott & White Heart & Vascular Institute – is participating in ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness), a nationwide aspirin study. Aspirin is a widely used, inexpensive therapy for preventing strokes and heart attacks in people living with heart disease. The goal of ADAPTABLE is to determine whether 81mg or 325mg of aspirin taken daily is more effective. The study will enroll 20,000 participants nationwide. Identifying the aspirin dose that works best could prevent as many as 88,000 deaths per year.
ADAPTABLE is a new type of clinical trial – patients can conveniently participate online and don’t have to make extra clinic visits for the study. REACHnet gathers healthcare data from patients’ electronic medical records to efficiently collect clinical information for the study. These innovative research methods save both time and money in comparison to traditional clinical research approaches.
To learn more about ADAPTABLE, click here.
Check out the ADAPTABLE Live Facebook Event celebrating Heart Month
On Monday, February 13th at 10:30 AM CST/11:30 AM EST, join the ADAPTABLE study and the American Heart Association for a LIVE Facebook Q&A session. This event will include cardiologists, study investigators, and a patient with heart disease who is enrolled in ADAPTABLE. Viewers are welcome to ask questions and learn more about this innovative clinical trial.
Meet the patient representatives that make ADAPTABLE a success
Patients work alongside ADAPTABLE researchers and clinicians to ensure that this study is a success from start to finish. Learn more about ADAPTABLE’s patient representative group, the Adaptors, by clicking here.